TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22463965

Group type: EXPERIMENTAL
Intervention: ECG technician (ECG-T)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Nursing staff assessment of intervention
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: ECG-to-EP time
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Diagnosis time
Number of subjects: 354
Study: 20394610

Group type: COMPARATOR
Intervention: Transobturator tape (TOT) - ARIS for the 'outside-in' route
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape-obturator (TVT) - O for the 'inside-out' route
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 341
Study: 18545059

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 3-12 mg/day
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 198
Study: 15917682

Group type: EXPERIMENTAL
Intervention: Intraosseous injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Infiltration injection
Number of subjects: 20
Study: 12692056

Group type: EXPERIMENTAL
Intervention: Interferon alfa 2b, 3 million units (MU), three times a week, and oral ribavirin (1000 mg/day)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Interferon 3 MU daily for the first four weeks and subsequently 3 MU three times a week, and ribavirin as in regimen A
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin as in regimen B, plus oral amantadine hydrochloride (200 mg/day)
Number of subjects: 114
Study: 10726917

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) coinfused with insulin from 120 to 240 minutes
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (insulin infusion using euglycemic clamp protocol for 240 minutes at a rate of 40 mU/m2/min for young and 34 mU/m2/min for old)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) coinfused with insulin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (insulin infusion)
Number of subjects: 19
Study: 8797404

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (500 micrograms)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1335641

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine, strain HM175, 720 ELISA units (El.U) on days 0 and 14
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine, strain HM175, 720 ELISA units (El.U) on days 0 and 28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine, strain HM175, 360 ELISA units (El.U) on days 0 and 28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine, strain HM175, 720 ELISA units (El.U) on days 0 and 14 (abbreviated schedule)
Number of subjects: 0
Study: 6206796

Group type: EXPERIMENTAL
Intervention: Adriamycin Nocardia rubra cell wall skeleton (N-CWS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Adriamycin (control group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intrapericardial instillation of anti-cancer drugs (Carbazilquinone, Mitomycin-C, ACNU) with pericardial drainage
Number of subjects: 55
Study: 2417474

Group type: EXPERIMENTAL
Intervention: Active treatment (4 treatment tracks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (1 treatment track)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment tracks (active and placebo)
Number of subjects: 0
Study: 30151212

Group type: EXPERIMENTAL
Intervention: Mirogabalin 50 and 75 mg single dose
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Mirogabalin (various doses)
Number of subjects: 125
Study: 26996385

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Veliparib (60 mg daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cyclophosphamide alone (50 mg once daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Veliparib
Number of subjects: 45
Study: 24102899

Group type: EXPERIMENTAL
Intervention: Intervention group (n=32) attended eight 2-hour group sessions once a week.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (n=31) did not receive the intervention.
Number of subjects: 63
Study: 22978196

Group type: EXPERIMENTAL
Intervention: Visual control training with a visual constraint (shooting with a screen blocking the basket)
Number of subjects: 0
Study: 19726418

Group type: EXPERIMENTAL
Intervention: Topiramate (mean dose 118 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 29
Study: 19323001

Group type: EXPERIMENTAL
Intervention: Regular exercise participation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 12
Study: 15892594

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin 40mg once daily
Number of subjects: 0
Study: 12699438

Group type: EXPERIMENTAL
Intervention: NN703 (3 mg/kg first dose, 1.5 mg/kg/day for 6 days)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: NN703
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: GHRH (1 micro g/kg)
Number of subjects: 97
Study: 11220764

Group type: EXPERIMENTAL
Intervention: Full-dose PRP-T Hib vaccine
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Half-dose PRP-T Hib vaccine
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: One-third-dose PRP-T Hib vaccine
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Full-dose PRP-T Hib vaccine combined with DTP
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Half-dose PRP-T Hib vaccine combined with DTP
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: One-third-dose PRP-T Hib vaccine combined with DTP
Number of subjects: 600
Study: 8837189

Group type: EXPERIMENTAL
Intervention: 2.5 mg droperidol
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 5 mg droperidol
Number of subjects: 210

Group type: COMPARATOR
Intervention: 2 mg morphine
Number of subjects: 210

Group type: COMPARATOR
Intervention: 4 mg morphine
Number of subjects: 210
Study: 1486261

Group type: EXPERIMENTAL
Intervention: 1,3,7-trimethylxanthine (800 mg in caffeinated coffee)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention, went to sleep at 2300 hours)
Number of subjects: 20
Study: 2981491

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2), 1 mg/ml
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 6-oxo-PGF1 alpha, 1 mg/ml
Number of subjects: 18

Group type: COMPARATOR
Intervention: Glycine vehicle
Number of subjects: 18
Study: 31468137

Group type: EXPERIMENTAL
Intervention: Veliparib 120 mg BID for 7 days in a 21-day cycle with carboplatin/paclitaxel
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Veliparib 120 mg BID
Number of subjects: 168
Study: 30499482

Group type: EXPERIMENTAL
Intervention: High-intensity pulsed magnetic field therapy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Medicamentous therapy with hymecromone and 'Sernovodskaya' mineral water
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Combined treatment including high-intensity pulsed magnetic field, mineral water, and pharmacotherapy
Number of subjects: 117
Study: 25645270

Group type: EXPERIMENTAL
Intervention: Combined verbal and numerical risk expressions (e.g. 'common: may affect up to 1 in 10 people')
Number of subjects: 339

Group type: COMPARATOR
Intervention: Numerical frequency bands (e.g. 'may affect up to 1 in 10 people')
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Risk qualifier verb manipulation ('may affect' or 'will affect')
Number of subjects: 339
Study: 24488143

Group type: EXPERIMENTAL
Intervention: T-DM1 (ado-trastuzumab emtansine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (lapatinib plus capecitabine)
Number of subjects: 0
Study: 22147671

Group type: EXPERIMENTAL
Intervention: Monophasic MCT at 50 μA for 35 hours
Number of subjects: 62

Group type: COMPARATOR
Intervention: Monophasic MCT at 500 μA for 35 hours
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Monophasic MCT at approximately 25 μA for 15 hours
Number of subjects: 62

Group type: COMPARATOR
Intervention: Monophasic MCT at approximately 25 μA for 189 hours
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pooled analysis of both trials
Number of subjects: 62
Study: 20394510

Group type: EXPERIMENTAL
Intervention: Distance learning program for pediatric asthma (Web- or CD-ROM-based multimedia learning modules and two teleconference calls)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Distance learning program for pediatric asthma
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 17912794

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing in addition to routine INR monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin therapy
Number of subjects: 0
Study: 16365000

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening intervention
Number of subjects: 1413
Study: 12048334

Group type: EXPERIMENTAL
Intervention: With handgrip (WG)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Without handgrip (WOHG)
Number of subjects: 9
Study: 11073849

Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 38
Study: 8806974

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 24
Study: 1623913

Group type: EXPERIMENTAL
Intervention: Indomethacin (dosage not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6475710

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 30954400

Group type: EXPERIMENTAL
Intervention: Nuclear myocardial perfusion imaging (MPI)
Number of subjects: 8889

Group type: COMPARATOR
Intervention: Coronary computed tomographic angiography (CTA)
Number of subjects: 8889

Group type: COMPARATOR
Intervention: Stress echocardiogram
Number of subjects: 8889

Group type: COMPARATOR
Intervention: Stress electrocardiogram
Number of subjects: 8889

Group type: EXPERIMENTAL
Intervention: Coronary angiography (Cath) following MPI
Number of subjects: 8889

Group type: COMPARATOR
Intervention: Coronary angiography (Cath) following CTA
Number of subjects: 8889

Group type: EXPERIMENTAL
Intervention: Radiation exposure
Number of subjects: 8889
Study: 30043965

Group type: EXPERIMENTAL
Intervention: Systematic Training for Effective Parenting (STEP)
Number of subjects: 17
Study: 28826068

Group type: EXPERIMENTAL
Intervention: Strength at Home‐Men's Program (SAH‐M)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 135
Study: 25462201

Group type: EXPERIMENTAL
Intervention: Unilateral TAP block with 30 cc of 0.25% bupivacaine with 3 mcg/mL epinephrine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Unilateral TAP block
Number of subjects: 64
Study: 23132642

Group type: EXPERIMENTAL
Intervention: Enteral neutral and acidic oligosaccharide supplementation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 21510271

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2T) administered seven days after surgery (n = 8) for 60 minutes at 2.5 ATA for five consecutive days after T2 stage.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group without HBO2T (n = 8).
Number of subjects: 16
Study: 18155284

Group type: EXPERIMENTAL
Intervention: Grass allergen tablet immunotherapy (GRAZAX)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 16582844

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: GP care
Number of subjects: 80
Study: 14519610

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Offering psychological intervention
Number of subjects: 0
Study: 10903015

Group type: EXPERIMENTAL
Intervention: Immediate hyperventilation (group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed hyperventilation (group D)
Number of subjects: 30
Study: 9091940

Group type: EXPERIMENTAL
Intervention: Double gloving
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Single gloving
Number of subjects: 1092
Study: 8452166

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for 7-14 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ofloxacin 200 mg twice daily for 7-14 days
Number of subjects: 80
Study: 3533419

Group type: EXPERIMENTAL
Intervention: ethinylestradiol/dl‐norgestrel combination
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: danazol
Number of subjects: 27
Study: 30487248

Group type: EXPERIMENTAL
Intervention: GAD gene therapy delivered into the subthalamic nucleus (STN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study: 27519144

Group type: EXPERIMENTAL
Intervention: Spironolactone (300mg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 93
Study: 24698572

Group type: EXPERIMENTAL
Intervention: Closed Reduction and Internal Fixation (CRIF)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 285
Study: 23737536

Group type: EXPERIMENTAL
Intervention: Quarter-dose DSA program with modified acquisition parameters
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference DSA program
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quarter-dose DSA program
Number of subjects: 20
Study: 20031260

Group type: EXPERIMENTAL
Intervention: Aspherical AcriSmart 36A IOL
Number of subjects: 25

Group type: COMPARATOR
Intervention: Zero-aberration AcriSmart 46LC IOL
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Whole population
Number of subjects: 25
Study: 18701205

Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing 2.5x10(9)CFU of L. rhamnosus GR‐1 and L. reuteri RC‐14
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 72
Study: 17043419

Group type: EXPERIMENTAL
Intervention: Milrinone (0.5 microg/kg/min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 50
Study: 14583409

Group type: EXPERIMENTAL
Intervention: Negative image training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study: 10999778

Group type: EXPERIMENTAL
Intervention: 750 mg calcium daily
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: 15 microg 25OH vitamin D3 daily
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study: 8668669

Group type: EXPERIMENTAL
Intervention: Ketoprofen 3% gel applied to the back
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketoprofen 3% gel applied to the arm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketoprofen 3% gel applied to the knee
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ketoprofen solution (60 mg/ml) applied to the back (reference treatment)
Number of subjects: 24
Study: 8155449

Group type: EXPERIMENTAL
Intervention: Artificial ventilation with isoflurane and nitrous oxide in oxygen and atracurium (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Spontaneous ventilation with isoflurane and nitrous oxide in oxygen (group B)
Number of subjects: 50
Study: 3048225

Group type: EXPERIMENTAL
Intervention: 0.5 mg scopolamine hydrobromide
Number of subjects: 9

Group type: COMPARATOR
Intervention: 1 mg oral lorazepam
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: 0.1 mg scopolamine hydrobromide
Number of subjects: 9

Group type: COMPARATOR
Intervention: 0.25 mg scopolamine hydrobromide
Number of subjects: 9
Study: 29178617

Group type: EXPERIMENTAL
Intervention: LY2584702
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2584702 with atorvastatin
Number of subjects: 0
Study: 28391397

Group type: EXPERIMENTAL
Intervention: Weight-lifting after 12 months
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 141
Study: 27754567

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus plus mycophenolate mofetil (Arm 1)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Prolonged-release tacrolimus plus sirolimus (Arm 2)
Number of subjects: 569
Study: 24101696

Group type: EXPERIMENTAL
Intervention: Acetyl‐L‐carnitine (52-week trial)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: HbA1c at baseline
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Support Vector Machine classifier using HbA1c
Number of subjects: 424
Study: 21192237

Group type: EXPERIMENTAL
Intervention: PF-04494700 10 mg (after a 6-day loading dose of 30 mg/d)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: PF-04494700 20 mg (after a loading dose of 60 mg/d)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: PF-04494700 (both doses)
Number of subjects: 67
Study: 19179904

Group type: EXPERIMENTAL
Intervention: Shorter duration of platinum-based therapy (3-4 cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Longer duration of platinum-based therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Earlier use of second-line therapy after completion of four cycles of platinum-based therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment paradigm of initiating second-line therapy upon disease progression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of targeted agents (bevacizumab or cetuximab) to initial chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with targeted agents
Number of subjects: 0
Study: 17355018

Group type: EXPERIMENTAL
Intervention: PRESTIGE ST Cervical Disc System (arthroplasty)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 541
Study: 15127155

Group type: EXPERIMENTAL
Intervention: Linac radiosurgery (median dose 20 Gy)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Linac radiosurgery
Number of subjects: 117

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 117
Study: 11520646

Group type: EXPERIMENTAL
Intervention: Very rapid enrollment
Number of subjects: 28992

Group type: EXPERIMENTAL
Intervention: Rapid enrollment
Number of subjects: 28992

Group type: EXPERIMENTAL
Intervention: Moderate enrollment
Number of subjects: 28992

Group type: EXPERIMENTAL
Intervention: Slow enrollment
Number of subjects: 28992

Group type: EXPERIMENTAL
Intervention: Initial rate of accrual
Number of subjects: 28992

Group type: EXPERIMENTAL
Intervention: Enrollment during the first month or two
Number of subjects: 28992
Study: 9924567

Group type: EXPERIMENTAL
Intervention: Kangaroo care
Number of subjects: 74

Group type: COMPARATOR
Intervention: Incubator care
Number of subjects: 74
Study: 8576531

Group type: EXPERIMENTAL
Intervention: Keeler Pulsair 2000
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tomey Pro‐Ton
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tono‐Pen XL
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Perkins
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Schiotz
Number of subjects: 31

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 31
Study: 2368961

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (3.75 mg/ml for 8 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide
Number of subjects: 8
Study: 351664

Group type: EXPERIMENTAL
Intervention: Relaxation Training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Relaxation plus Assertive Training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assertive Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication and leaderless group
Number of subjects: 0
Study: 30149204

Group type: EXPERIMENTAL
Intervention: Dieting prime
Number of subjects: 225

Group type: COMPARATOR
Intervention: Neutral prime
Number of subjects: 225
Study: 28925059

Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer (once-weekly application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciclopirox 8% nail lacquer (once-daily application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urea 40% ointment/bifonazole 1% cream combination (once-daily application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urea 40% ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bifonazole 1% cream
Number of subjects: 0
Study: 25456892

Group type: EXPERIMENTAL
Intervention: Integrated health management model
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 22882570

Group type: EXPERIMENTAL
Intervention: One-lung ventilation (OLV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Two-lung ventilation (TLV)
Number of subjects: 30
Study: 21997779

Group type: EXPERIMENTAL
Intervention: Bryan(®) cervical disc prosthesis
Number of subjects: 83

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 83
Study: 18294021

Group type: EXPERIMENTAL
Intervention: Intramuscular risperidone, 25 mg every other week
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (risperidone and placebo)
Number of subjects: 31
Study: 16579924

Group type: COMPARATOR
Intervention: Fulguration with ball electrode
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Monsel's paste
Number of subjects: 100
Study: 12686367

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa and bulimia nervosa subjects (271 total)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Matched normal control group (271 total)
Number of subjects: 271